Total Payments
$19,733
2024 Payments
$201.13
Companies
33
Transactions
143
Medicare Patients
2,454
Medicare Billing
$183,281
Payment Breakdown by Category
Other$10,700 (54.2%)
Food & Beverage$6,162 (31.2%)
Travel$1,864 (9.4%)
Consulting$750.00 (3.8%)
Education$256.12 (1.3%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $10,700 | 3 | 54.2% |
| Food and Beverage | $6,162 | 130 | 31.2% |
| Travel and Lodging | $1,864 | 3 | 9.4% |
| Consulting Fee | $750.00 | 2 | 3.8% |
| Education | $256.12 | 5 | 1.3% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $14,734 | 40 | $0 (2024) |
| Genentech USA, Inc. | $582.33 | 7 | $0 (2019) |
| Celgene Corporation | $497.99 | 11 | $0 (2019) |
| TESARO, Inc. | $338.96 | 4 | $0 (2019) |
| Pharmacyclics LLC, an AbbVie Company | $318.84 | 5 | $0 (2022) |
| AstraZeneca Pharmaceuticals LP | $317.80 | 6 | $0 (2021) |
| PUMA BIOTECHNOLOGY, INC. | $298.87 | 6 | $0 (2022) |
| Clovis Oncology, Inc. | $230.65 | 3 | $0 (2019) |
| Janssen Biotech, Inc. | $218.29 | 5 | $0 (2024) |
| Takeda Pharmaceuticals U.S.A., Inc. | $198.31 | 2 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $201.13 | 2 | E.R. Squibb & Sons, L.L.C. ($127.00) |
| 2023 | $508.30 | 5 | E.R. Squibb & Sons, L.L.C. ($176.96) |
| 2022 | $798.30 | 9 | E.R. Squibb & Sons, L.L.C. ($283.18) |
| 2021 | $110.10 | 2 | AstraZeneca Pharmaceuticals LP ($98.18) |
| 2019 | $1,324 | 15 | Genentech USA, Inc. ($247.15) |
| 2018 | $1,797 | 48 | E.R. Squibb & Sons, L.L.C. ($651.69) |
| 2017 | $14,994 | 62 | E.R. Squibb & Sons, L.L.C. ($13,353) |
All Payment Transactions
143 individual payment records from CMS Open Payments — Page 1 of 6
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 10/23/2024 | Janssen Biotech, Inc. | DARZALEX (Biological), TECVAYLI | Food and Beverage | In-kind items and services | $74.13 | General |
| Category: Oncology | ||||||
| 04/10/2024 | E.R. Squibb & Sons, L.L.C. | REBLOZYL (Biological) | Food and Beverage | Cash or cash equivalent | $127.00 | General |
| Category: Hematology | ||||||
| 09/27/2023 | E.R. Squibb & Sons, L.L.C. | REBLOZYL (Biological) | Food and Beverage | Cash or cash equivalent | $93.39 | General |
| Category: Hematology | ||||||
| 04/26/2023 | Karyopharm Therapeutics Inc. | XPOVIO (Drug) | Food and Beverage | In-kind items and services | $114.30 | General |
| Category: Oncology | ||||||
| 03/16/2023 | Seagen Inc. | PADCEV (Biological) | Food and Beverage | In-kind items and services | $120.26 | General |
| Category: Oncology | ||||||
| 02/23/2023 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Food and Beverage | Cash or cash equivalent | $83.57 | General |
| Category: Oncology | ||||||
| 01/25/2023 | Takeda Pharmaceuticals U.S.A., Inc. | NINLARO (Drug) | Food and Beverage | In-kind items and services | $96.78 | General |
| Category: ONCOLOGY | ||||||
| 11/09/2022 | PharmaEssentia USA Corporation | BESREMI (Drug) | Food and Beverage | In-kind items and services | $95.25 | General |
| Category: Oncology | ||||||
| 10/26/2022 | E.R. Squibb & Sons, L.L.C. | Pomalyst (Drug) | Food and Beverage | Cash or cash equivalent | $89.18 | General |
| Category: Hematology | ||||||
| 09/29/2022 | GlaxoSmithKline, LLC. | BLENREP (Biological) | Food and Beverage | In-kind items and services | $70.27 | General |
| Category: ONCOLOGY | ||||||
| 07/06/2022 | GlaxoSmithKline, LLC. | BLENREP (Biological) | Food and Beverage | In-kind items and services | $95.25 | General |
| Category: ONCOLOGY | ||||||
| 06/22/2022 | E.R. Squibb & Sons, L.L.C. | REBLOZYL (Biological) | Food and Beverage | Cash or cash equivalent | $87.14 | General |
| Category: Hematology | ||||||
| 06/08/2022 | Janssen Biotech, Inc. | DARZALEX (Biological) | Food and Beverage | In-kind items and services | $73.03 | General |
| Category: Oncology | ||||||
| 05/18/2022 | PUMA BIOTECHNOLOGY, INC. | NERLYNX (Drug) | Food and Beverage | In-kind items and services | $90.83 | General |
| Category: ONCOLOGY | ||||||
| 04/20/2022 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Food and Beverage | Cash or cash equivalent | $106.86 | General |
| Category: Oncology | ||||||
| 03/30/2022 | Pharmacyclics LLC, an AbbVie Company | IMBRUVICA (Drug) | Food and Beverage | In-kind items and services | $90.49 | General |
| Category: ONCOLOGY | ||||||
| 06/16/2021 | AstraZeneca Pharmaceuticals LP | LYNPARZA (Drug) | Food and Beverage | In-kind items and services | $98.18 | General |
| Category: Oncology | ||||||
| 06/01/2021 | Gilead Sciences, Inc. | — | Education | In-kind items and services | $11.92 | General |
| 11/13/2019 | Incyte Corporation | JAKAFI (Drug) | Food and Beverage | Cash or cash equivalent | $125.00 | General |
| Category: Hematology/Oncology | ||||||
| 10/23/2019 | AstraZeneca Pharmaceuticals LP | LYNPARZA (Drug) | Food and Beverage | In-kind items and services | $80.11 | General |
| Category: Oncology | ||||||
| 10/02/2019 | Novartis Pharmaceuticals Corporation | GLEEVEC (Drug) | Food and Beverage | In-kind items and services | $55.00 | General |
| Category: ONCOLOGY | ||||||
| 09/05/2019 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Food and Beverage | Cash or cash equivalent | $125.00 | General |
| Category: Oncology | ||||||
| 08/21/2019 | Clovis Oncology, Inc. | Rubraca (Drug) | Food and Beverage | In-kind items and services | $119.76 | General |
| Category: Oncology | ||||||
| 07/10/2019 | E.R. Squibb & Sons, L.L.C. | EMPLICITI (Biological) | Food and Beverage | Cash or cash equivalent | $17.15 | General |
| Category: Oncology | ||||||
| 06/27/2019 | Genentech USA, Inc. | TECENTRIQ (Biological) | Food and Beverage | In-kind items and services | $128.63 | General |
| Category: BioOncology | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 7 | 571 | 681 | $147,988 | $50,258 |
| 2022 | 7 | 565 | 652 | $111,910 | $36,368 |
| 2021 | 7 | 577 | 742 | $122,488 | $40,396 |
| 2020 | 13 | 741 | 1,107 | $195,768 | $56,259 |
Total Patients
2,454
Total Services
3,182
Medicare Billing
$183,281
Procedure Codes
37
All Medicare Procedures & Services
37 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 229 | 319 | $68,547 | $24,819 | 36.2% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2023 | 163 | 180 | $28,593 | $8,950 | 31.3% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Facility | 2023 | 53 | 53 | $18,027 | $5,723 | 31.7% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Facility | 2023 | 76 | 76 | $15,114 | $4,766 | 31.5% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2023 | 28 | 31 | $10,732 | $3,650 | 34.0% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2023 | 11 | 11 | $4,888 | $1,634 | 33.4% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 11 | 11 | $2,088 | $715.33 | 34.3% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2022 | 246 | 316 | $45,181 | $15,209 | 33.7% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 100 | 111 | $23,852 | $8,213 | 34.4% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Facility | 2022 | 110 | 110 | $21,876 | $7,048 | 32.2% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Facility | 2022 | 31 | 31 | $10,544 | $3,011 | 28.6% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Facility | 2022 | 34 | 37 | $2,657 | $1,034 | 38.9% |
| 99442 | Telephone medical discussion with physician, 11-20 minutes | Office | 2022 | 19 | 20 | $3,963 | $717.70 | 18.1% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2022 | 11 | 11 | $2,188 | $629.98 | 28.8% |
| 99231 | Follow-up hospital inpatient care per day, typically 15 minutes | Facility | 2022 | 14 | 16 | $1,650 | $506.24 | 30.7% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Facility | 2021 | 332 | 475 | $70,860 | $25,001 | 35.3% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 65 | 73 | $16,625 | $5,854 | 35.2% |
| 99203 | New patient outpatient visit, total time 30-44 minutes | Facility | 2021 | 46 | 46 | $10,088 | $2,871 | 28.5% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 15 | 25 | $4,745 | $1,476 | 31.1% |
| 99442 | Physician telephone patient service, 11-20 minutes of medical discussion | Office | 2021 | 31 | 33 | $6,539 | $1,409 | 21.5% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Facility | 2021 | 14 | 14 | $5,134 | $1,353 | 26.3% |
| 99212 | Established patient outpatient visit, total time 10-19 minutes | Facility | 2021 | 47 | 47 | $3,451 | $1,223 | 35.4% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 27 | 29 | $5,047 | $1,211 | 24.0% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Facility | 2020 | 264 | 541 | $81,226 | $21,736 | 26.8% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Facility | 2020 | 112 | 167 | $37,118 | $9,860 | 26.6% |
About Dr. David Lovett, MD
Dr. David Lovett, MD is a Medical Oncology healthcare provider based in Hyannis, Massachusetts. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 03/09/2006. The National Provider Identifier (NPI) number assigned to this provider is 1790753283.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. David Lovett, MD has received a total of $19,733 in payments from pharmaceutical and medical device companies, with $201.13 received in 2024. These payments were reported across 143 transactions from 33 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($10,700).
As a Medicare-enrolled provider, Lovett has provided services to 2,454 Medicare beneficiaries, totaling 3,182 services with total Medicare billing of $183,281. Data is available for 4 years (2020–2023), covering 37 distinct procedure/service records.
Ad
Practice Information
- Specialty Medical Oncology
- Location Hyannis, MA
- Active Since 03/09/2006
- Last Updated 07/08/2007
- Taxonomy Code 207RX0202X
- Entity Type Individual
- NPI Number 1790753283
Products in Payments
- OPDIVO (Biological) $14,269
- TECENTRIQ (Biological) $386.49
- Revlimid (Drug) $336.56
- ZEJULA (Drug) $317.22
- REBLOZYL (Biological) $307.53
- NINLARO (Drug) $241.90
- Rubraca (Drug) $230.65
- Imbruvica (Drug) $228.35
- Nerlynx (Drug) $208.04
- Avastin (Biological) $195.84
- LYNPARZA (Drug) $178.29
- Cabometyx (Drug) $167.41
- BLENREP (Biological) $165.52
- Abraxane (Drug) $161.43
- DARZALEX (Biological) $147.16
- IMFINZI (Drug) $125.65
- JAKAFI (Drug) $125.00
- PADCEV (Biological) $120.26
- XPOVIO (Drug) $114.30
- BENDEKA (Drug) $114.27
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.